Vor Biopharma Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
Vor Biopharma Inc. (VOR) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent of 0.40% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch · last filed 2026-03-30
- Vor Biopharma Inc. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2025 was 0.40%, a 91.67% decline from fiscal 2024.
- Vor Biopharma Inc. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2024 was 4.80%, a 15.79% decline from fiscal 2023.
- Vor Biopharma Inc. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2023 was 5.70%, a 3.64% increase from fiscal 2022.
- Vor Biopharma Inc. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2022 was 5.50%, a 34.15% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent 12 month |
|---|---|
| 2025-12-31 | 0.40% 10-K · filed 2026-03-30 |
| 2024-12-31 | 4.80% 10-K · filed 2026-03-30 |
| 2023-12-31 | 5.70% 10-K · filed 2025-03-20 |
| 2022-12-31 | 5.50% 10-K · filed 2024-03-20 |
| 2021-12-31 | 4.10% 10-K · filed 2023-03-23 |
| 2020-12-31 | 5.80% 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |